GO
| HSI1 | 23,393.32 | 0.00 | -- |
| HSCEI1 | 7,906.11 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2026-11-02 18:25:32 Citi published a research report stating that ESMO 2026 marked another important step forward for China's pharmaceutical and biotechnology sectors. China-developed original assets delivered compelling data across multiple key global studies, demonstrating strong China-to-global consistency, highly watched clinical results, and innovation beyond established targets. The bank believes this helps reduce sector risk, strengthens confidence in global regulatory pathways, overseas commercialization, and the sustainability of cross-border partnerships, and could support structural re-rating for companies with differentiated and internationally competitive pipelines. The bank noted that several closely watched readouts exceeded investor expectations, including the 15.0-month median progression-free survival in OptiTROP-Lung06, as well as statistically significant progression-free survival and overall survival benefits achieved in HARMONi-GI1. The industry is also seeing a growing number of positive results from randomized and registrational studies, rather than relying mainly on early-stage single-arm data. Improved quality and maturity of clinical evidence should help enhance asset visibility and shift investor focus toward regulatory execution, launch readiness, and commercialization. The bank added that it remains positive on companies with globally validated assets, sufficiently differentiated pipelines, and clear catalysts. Its top picks in the pharmaceutical sector are CSPC PHARMA (01093.HK) and HENGRUI PHARMA (01276.HK), while its preferred biopharmaceutical names are INNOVENT BIO (01801.HK) and SKB BIO (06990.HK). It is also positive on HUTCHMED (00013.HK). (da/u)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |